Apellis Pharmaceuticals, Inc. · NASDAQ:APLS
Apellis Pharmaceuticals — Q4 2023 Earnings Presentation
13 slides from Apellis Pharmaceuticals's earnings presentation, Feb 27, 2024
Slide 1: Fourth Quarter and Full Year 2023 Financial Results Conference Call
Fourth Quarter and Full Year 2023 Financial Results Conference Call February 27, 2024
Slide 2: Apellis Participants
Apellis Participants CEDRIC FRANCOIS, M.D., Ph.D. Co-Founder, President & Chief Executive Officer ADAM TOWNSEND Chief Operating Officer CAROLINE BAUMAL, M.D. Chief Medical Officer T I M O T H Y S U L L I VA N Chief Financial Officer 2
Slide 3: Forward-looking statements
Forward-looking statements Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act
Slide 4: SYFOVRE and EMPAVELI making meaningful differences for patients
SYFOVRE and EMPAVELI making meaningful differences for patients ✓ >200,000 doses delivered to ECPs since ✓ ~$24M in 4Q 2023 U.S. net product launch through mid-February 2024 revenue; ~$91M in FY 2023 ✓ ~215,000 injections estimated through mid-February 2024 (incl. Ph3 trials) ✓ 97% compliance rate ✓
Slide 5: 2024 priorities support multiple drivers of future growth
2024 priorities support multiple drivers of future growth 1 2 3 4 Reach more U.S. Bring SYFOVRE to Maximize Advance early patients with GA patients with GA EMPAVELI in PNH & pipeline and Beam worldwide C3G/IC-MPGN collaboration … with compassion and commitment to patients 5
Slide 6: SYFOVRE is the #1 chosen GA treatment in the U.S.
SYFOVRE is the #1 chosen GA treatment in the U.S. • ~62,000 doses delivered to ECPs in 4Q 2023; >160,000 doses delivered as of 12/31/231 • Double-digit number of new sites each week1 • Strong payer coverage with permanent J-code effective as of 10/1/23 • Despite some seasonality, January and Februar
Slide 7: Key advantages of SYFOVRE expected to further strengthen launch momentum
Key advantages of SYFOVRE expected to further strengthen launch momentum More efficacy over time More experience More vision saved for patients 1. Contextualization and support for the statements on this slide are included in the associated Investor Call on February 27 , 2024 and Apellis’ J.P. Morga
Slide 8: EMPAVELI is elevating the standard of care in PNH
EMPAVELI is elevating the standard of care in PNH As of December 31, 2023: • ~$91 million in FY 2023 U.S. net product sales – ~$24 million in 4Q 2023 U.S. net product sales • ~10% of demand in 2023 was from treatment- naïve patients • 97% patient compliance rate • Continued strong safety profile • P
Slide 9: Significant presence at recent medical meetings
Significant presence at recent medical meetings 9
Slide 10: VALIANT Phase 3 study: patient enrollment complete, top-line data expected mid-2024
VALIANT Phase 3 study: patient enrollment complete, with top- line data study expected mid-2024 Primary endpoint readout Up to 8 weeks 26 weeks 26 weeks 8 weeks Population: Patients 12 Screening Randomized, double-blind Open-label period Follow-up* years+ with C3G or primary controlled period IC-MPG
Slide 11: Consolidated fourth quarter and full year 2023 financial results
Consolidated fourth quarter and full year 2023 financial results (In USD Millions) Three Months Ended December 31, Twelve Months Ended December 31, 2023 2022 2023 2022 EMPAVELI U.S. Net Product Sales $24.4 $19.7 $91.0 $65.1 SYFOVRE U.S. Net Product Sales $114.3 -- $275.2 -- Licensing and Other Reven
Slide 12: 2024 priorities support multiple drivers of future growth
2024 priorities support multiple drivers of future growth 1 2 3 4 Reach more U.S. Bring SYFOVRE to Maximize Advance early patients with GA patients with GA EMPAVELI in PNH & pipeline and Beam worldwide C3G/IC-MPGN collaboration … with compassion and commitment to patients 12
Slide 13: Fourth Quarter and Full Year 2023 Financial Results Conference Call
Fourth Quarter and Full Year 2023 Financial Results Conference Call February 27, 2024
Apellis Pharmaceuticals — Q4 2023 Earnings Presentation on 6ix